R
Raymond S. McDermott
Researcher at University College Dublin
Publications - 8
Citations - 2753
Raymond S. McDermott is an academic researcher from University College Dublin. The author has contributed to research in topics: Axitinib & Pembrolizumab. The author has an hindex of 6, co-authored 8 publications receiving 1450 citations. Previous affiliations of Raymond S. McDermott include Georgetown University.
Papers
More filters
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles,Elizabeth R. Plimack,Denis Soulières,T. Waddell,Viktor Stus,Rustem Gafanov,Dmitry Nosov,Frédéric Pouliot,Bohuslav Melichar,Ihor Vynnychenko,Sergio J Azevedo,Delphine Borchiellini,Raymond S. McDermott,Jens Bedke,Satoshi Tamada,Lina Yin,Mei Chen,L Rhoda Molife,Michael B. Atkins,Brian I. Rini,Brian I. Rini +20 more
TL;DR: With extended study follow-up, results from KEYNOTE-426 show that pembrolizumab plus axitinib continues to have superior clinical outcomes over sunit inib, and these results continue to support the first-line treatment with pembroizumAB plus ax itinib as the standard of care of advanced renal cell carcinoma.
Journal ArticleDOI
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Sergio J Azevedo,Delphine Borchiellini,Raymond S. McDermott,Jens Bedke,Satoshi Tamada,Shuyan (Sabrina) Wan,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +19 more
TL;DR: Pembro + axi significantly improved OS, PFS, and ORR vs sunitinib and had manageable toxicity a year after pembro - axi treatment, according to KEYNOTE-426.
Journal ArticleDOI
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Thomas K. Waddell,Rustem Gafanov,Frédéric Pouliot,Dmitry Nosov,Bohuslav Melichar,Denis Soulières,Delphine Borchiellini,Ihor Vynnychenko,Raymond S. McDermott,Sergio J Azevedo,Satoshi Tamada,Anna Kryzhanivska,Chenxiang Li,J. Burgents,L Rhoda Molife,Jens Bedke,Thomas Powles +19 more
TL;DR: Treatment with pembro + axi significantly improved OS, PFS, and ORR vs sunitinib monotherapy in treatment-naive advanced ccRCC, and this is the longest follow-up of an anti-PD–1/L1 immunotherapy combined with a VEGF/VEGFR inhibitor.
Journal ArticleDOI
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.
Bertrand F. Tombal,Yohann Loriot,Fred Saad,Raymond S. McDermott,Tony Elliott,Alejo Rodriguez-Vida,Franco Nolè,Beatrice Fournier,Laurence Collette,Silke Gillessen +9 more
TL;DR: This data indicates that conventional chemotherapy for metastatic castration resistant prostate cancer may cause skeletal fractures, which are a frequent and underestimated side-effect of systemic treatment, to be more widespread in women than in men.